A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease

Last updated: September 24, 2016
Sponsor: Medivation, Inc.
Overall Status: Terminated

Phase

3

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT00954590
DIM19
  • Ages > 50
  • All Genders

Study Summary

The purpose of this study is to determine if Dimebon is safe and effective in patients with moderate to severe Alzheimer's disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Moderate-to-Severe Alzheimer's disease

  • Mini-Mental State Examination (MMSE) Score between 5 to 14, inclusive

  • Stable on donepezil for at least 6 months

Exclusion

Exclusion Criteria:

  • Other causes of dementia

  • Major structural brain disease

  • Unstable medical condition or significant hepatic or renal disease

Study Design

Total Participants: 89
Study Start date:
October 01, 2009
Estimated Completion Date:

Connect with a study center

  • Santiago,
    Chile

    Site Not Available

  • Glasgow, Scotland
    United Kingdom

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.